INCB024360
Drug timelines are a Plus or Pro feature.
4 regulatory and trial events tracked for INCB024360, covering 2016-01-18 to 2023-02-24. Get the full timeline:
Most recent: Clinical Trial Update: DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, and IDO1 Inhibitor INCB024360 in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission [Phase 1, Phase 2]